Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198658 | 0.79 | NPC1 (0.44) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL19311639 | 0.78 | FBP1 (0.42) | POLB | |
| SCHEMBL13471211 | 0.77 | GAA (0.41) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL18683558 | 0.74 | FBP1 (0.56) | MAPTRAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL29644185 | 0.74 | GAA (0.50) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL3791857 | 0.74 | GAA (0.48) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL19221871 | 0.73 | GAA (0.34) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL3729632 | 0.72 | — | — | |
| SCHEMBL18026717 | 0.71 | GAA (0.52) | GAAL3MBTL1MAPTPKMRAB9A | |
| SCHEMBL3379221 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240069439-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF USE | EASTMAN KODAK COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240069439-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF USE | EASTMAN KODAK COMPANY | 2024-02-29 | — | — | US | disclosed |
| WO-2020099858-A1 | CEPHALOSPORIN CIPROFLOXACIN HYBRID COMPOUNDS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-10172821-B2 | Histone deacetylase inhibitors | President & Fellows of Harvard College Dana-Farber Cancer Institute, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9963467-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080176825-A1 | Oral Neurotherapeutic Cefazolin Compositons | REVAAX PHARMACEUTICALS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | GAA 892/4885L3MBTL1 1131/4885MAPT 3313/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | GAA 440/4885L3MBTL1 2995/4885MAPT 87/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | GAA 363/4885L3MBTL1 1534/4885MAPT 1317/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | GAA 220/4885L3MBTL1 3681/4885MAPT 4488/4885 |
| US-20080176825-A1 | Oral Neurotherapeutic Cefazolin Compositons | BDNF, PRSS12, PYGB | GAA 3289/4885L3MBTL1 3644/4885MAPT 157/4885 |
| US-20170136047-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | GAA 76/4885L3MBTL1 1538/4885MAPT 3247/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | GAA 299/4885L3MBTL1 3510/4885MAPT 4489/4885 |
| US-10172821-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC7 | GAA 363/4885L3MBTL1 1534/4885MAPT 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.